rbd003

Robert B. Den, MD

Contact Dr. Den

111 South 11th Street
Room G-301, Bodine Center
Philadelphia, PA 19107

(215) 955-6702
(215) 955-0412 fax

Most Recent Peer-reviewed Publications

  1. Current perspectives on bone metastases in castrate-resistant prostate cancer
  2. Decision Support and Shared Decision Making About Active Surveillance Versus Active Treatment Among Men Diagnosed with Low-Risk Prostate Cancer: a Pilot Study
  3. Role of genetic testing for inherited prostate cancer risk: Philadelphia prostate cancer consensus conference 2017
  4. TOP2A and EZH2 provide early detection of an aggressive prostate cancer subgroup
  5. Low rates of androgen deprivation therapy use with salvage radiation therapy in patients with prostate cancer after radical prostatectomy
  6. The role of genomic techniques in predicting response to radiation therapy
  7. Increasing faculty participation in resident education and providing cost-effective self-assessment module credit to faculty through resident-generated didactics
  8. Genomic classifier augments the role of pathological features in identifying optimal candidates for adjuvant radiation therapy in patients with prostate cancer: Development and internal validation of a multivariable prognostic model
  9. Individual patient-level meta-Analysis of the performance of the decipher genomic classifier in high-risk men after prostatectomy to predict development of metastatic disease
  10. Transcriptome evaluation of the relation between body mass index and prostate cancer outcomes
  11. Neuropilin-1 is upregulated in the adaptive response of prostate tumors to androgen-targeted therapies and is prognostic of metastatic progression and patient mortality
  12. Cost-effectiveness of the Decipher Genomic Classifier to Guide Individualized Decisions for Early Radiation Therapy After Prostatectomy for Prostate Cancer
  13. siRNA-Encapsulated Hybrid Nanoparticles Target Mutant K-ras and Inhibit Metastatic Tumor Burden in a Mouse Model of Lung Cancer
  14. MicroRNA-194 promotes prostate cancer metastasis by inhibiting SOCS2
  15. RB loss promotes prostate cancer metastasis
  16. Low PCA3 expression is a marker of poor differentiation in localized prostate tumors: Exploratory analysis from 12,076 patients
  17. Prognostic outlier genes for enhanced prostate cancer treatment
  18. Multi-institutional Analysis Shows that Low PCAT-14 Expression Associates with Poor Outcomes in Prostate Cancer
  19. Do Prostate Cancer Patients with Markedly Elevated PSA Benefit from Radiation Therapy?
  20. Hematologic Toxicity of Concurrent Administration of Radium-223 and Next-generation Antiandrogen Therapies